Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
J Endocrinol Invest. 2022 Dec;45(12):2283-2289. doi: 10.1007/s40618-022-01863-x. Epub 2022 Jul 12.
SARS-CoV-2 infection can be associated with destructive thyroiditis and triggers thyroid autoimmunity. More recent evidence suggests that SARS-CoV-2 vaccines may also be associated with permanent or transient thyroid dysfunction in susceptible individuals.
We observed three patients who developed/exacerbated autoimmune thyroid diseases (AITDs) shortly after receiving mRNA-based vaccines against SARS-CoV2. Clinical histories are reported, and relevant literature in the field is summarized.
Our case series gives a description of the full spectrum of autoimmune disorders that may occur after SARS-CoV-2 vaccines administration, ranging from a case of new-onset Graves' disease to autoimmune hypothyroidism in two patients with pre-existing AITDs. Our three patients had a personal and/or family history of autoimmune disorders, suggesting that genetic predisposition is an important risk factor for the development of AITDs following vaccination. Moreover, our real-life experience demonstrates that persistent hypothyroidism may occur in the long run and should be overlooked; subjects with a previous AITDs are at risk of developing it. Reviewing the pertinent literature up to date Graves' disease is the most common vaccine-related AITDs with up to 51 cases reported in the literature, occurring mainly in female patients with no personal history of AIDTs, while only a case of autoimmune hypothyroidism has been reported so far.
SARS-CoV-2 vaccines can trigger autoimmune reactions and the present case series contributes to make clinicians aware of full spectrum of AITDs that may occur following vaccination. Thyroid function monitoring is recommended, mainly in subjects with a personal/family history of AITDs.
SARS-CoV-2 感染可引起破坏性甲状腺炎并引发甲状腺自身免疫。最近的证据表明,SARS-CoV-2 疫苗也可能与易感个体的永久性或暂时性甲状腺功能障碍有关。
我们观察了 3 名在接种 SARS-CoV2 的 mRNA 疫苗后不久发生/加重自身免疫性甲状腺疾病(AITD)的患者。报告了临床病史,并总结了该领域的相关文献。
我们的病例系列描述了可能在 SARS-CoV-2 疫苗接种后发生的自身免疫障碍的全貌,范围从新发 Graves 病到两名患有预先存在的 AITD 的患者的自身免疫性甲状腺功能减退症。我们的三名患者有自身免疫性疾病的个人和/或家族史,这表明遗传易感性是接种疫苗后发生 AITD 的重要危险因素。此外,我们的真实经验表明,持续性甲状腺功能减退症可能会长期发生,不应被忽视;既往患有 AITD 的患者有发病风险。回顾目前的相关文献,Graves 病是最常见的与疫苗相关的 AITD,文献中报告了多达 51 例,主要发生在没有自身免疫性疾病个人史的女性患者中,而迄今为止仅报告了 1 例自身免疫性甲状腺功能减退症。
SARS-CoV-2 疫苗可引发自身免疫反应,本病例系列有助于临床医生了解接种疫苗后可能发生的 AITD 的全貌。建议进行甲状腺功能监测,主要针对有自身免疫性疾病个人/家族史的患者。